Table 2.
Response and relapse outcomes in trials assessing CD19 CAR-T therapy with CD28/CD3ζ co-stimulatory domains in B-cell acute lymphoblastic leukemia with potential bridging to allogeneic hematopoietic cell transplantation.
| Lee et al. (57) | Park et al. (58) | Curran et al. (59) | |
|---|---|---|---|
| Patients, n | 51 | 53 | 25 |
| Age Category | Pediatric and YA | Adult | Pediatric and YA |
| Median follow-up, mo | 22.5 | 29 | 7.7 (28.6 in responders) |
| Prior allo-HCT, % | 35 | 36 | 20 |
| CR(MRD-), % | 61(55) | 83(60) | 75 (67) |
| Allo-HCT post-CR,% | 75 | 39 | 83 |
| Relapse after CR: overall/after allo-HCT % | 29/9.5 | 56/35 | 33/27 |
Allo-HCT, allogeneic hematopoietic cell transplantation; CR, complete remissions; MRD, minimal residual disease; YA, young adults.